Getting started with CRISPR whole genome screening has never been easier with the NEW Dharmacon All-in-one CRISPR platform.
11 result(s)
The Role of Revvity’s Cell Line in Supporting Wellcome Sanger Institute's genome variant exploration
A blog article demonstrating how Revvity and Wellcome Sanger Institute partnered to generate a HAP1 LIG4(-) Cas9(+) cell line in support of the Atlas of Variant Effects (AVE) alliance.
Functional genomic screening allows for the elucidation of the mechanism of action of exogenous agents which modulate intracellular gene function such as pharmaceutical agents and other compounds. Read about the various considerations, approaches and interpretations when conducting a screen to investigate novel compounds and analyzing the screening data.
In pooled CRISPR drug-gene screens two selection mechanisms can be applied, positive or resistance and negative or sensitivity screening, with each having various considerations and uses
A study where we have employed orthogonal target validation strategies with 3 orthogonal LOF technologies (CRISPRko, CRISPRi, and siRNA) with genes involved in maintenance of the mesenchymal-to-epithelial transition (MET).
Reliable and consistent quality reagents are critical to experimental success and reproducibility. Learn about how Dharmacon RNA and DNA oligonucleotide synthesis delivers that level of quality, and explore troubleshooting tips for investigating unexpected results in your experiments.
The reasoning and research behind our Dharmacon™ CRISPRi platform recently published in The CRISPR Journal.
Learn about methods for CRISPR activation and determine the best path for your preferred cell model and experimental parameters.
The presence of off-targets effects can greatly complicate the interpretation of experimental data. Dharmacon™ ON-TARGETplus™ siRNAs and CRISPRmod CRISPRi system are designed to knock down the target gene with minimal off-target effects and are powerful tools for orthogonal validation strategies resulting in highly specific readouts.
Gene modulation is now more flexible and accessible thanks to Horizon's new CRISPRmod CRISPRi portfolio. The system leverages an inactive Cas9 complex to block transcription resulting in precision targeted gene down regulation. Read more about our newest offering: